Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Freezor modification

This article was originally published in The Gray Sheet

Executive Summary

CryoCath's FreezorXtra, the larger version of the Freezor cryoablation catheter, is now available to a limited number of U.S. electrophysiologists after earning 510(k) clearance for epicardial ablation, the Montreal company announces May 8. Until the company's clinical advisory board completes a comprehensive dissemination plan later this year, the device will be targeted to operators familiar with the epicardial arrhythmia ablation technique pioneered by Eduardo Sosa, MD, University of Sao Paulo. On April 22, Freezor was approved for treating atrioventricular node re-entry tachycardia (1"The Gray Sheet" May 5, 2003, In Brief)...

You may also be interested in...

CryoCath clarification

FDA-approved labeling for CryoCath's Freezor ablation catheter, PMA-approved April 22, includes directions for performing cryomapping prior to cryoablation of atrioventricular node re-entry tachycardia. However, the Freezor's instructions for use do not list cryomapping as a specific indication, as was reported in "The Gray Sheet" (April 28, p. 5)...

Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders

Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts